<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Synthetic <z:chebi fb="0" ids="25676">oligopeptides</z:chebi> have emerged as a promising class of targeting ligands, providing a variety of choices for the construction of conjugates for desired ligand functionality </plain></SENT>
<SENT sid="1" pm="."><plain>To explore the potential of short <z:chebi fb="7" ids="16670">peptides</z:chebi> as ligands for targeted delivery of macromolecular therapeutics for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), fluorescently labelled <z:chebi fb="0" ids="53440">HPMA</z:chebi> <z:chebi fb="5" ids="53310">copolymers</z:chebi>--bearing either G3-C12 or GE11 for targeting galectin-3 and epidermal growth factor receptor (EGFR), respectively--were synthesised and the mechanisms of their internalisation and subcellular fate in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells were studied </plain></SENT>
<SENT sid="2" pm="."><plain>The targetability of the G3-C12 bearing <z:chebi fb="5" ids="53310">copolymers</z:chebi> towards galectin-3 was further compared to that of <z:chebi fb="1" ids="28260">galactose</z:chebi>-containing <z:chebi fb="5" ids="53310">copolymers</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The resulting G3-C12-bearing conjugate actively and selectively targets <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells over-expressing galectin-3 and exhibits superior targetability to galectin-3 when compared to the <z:chebi fb="1" ids="28260">galactose</z:chebi>-bearing <z:chebi fb="5" ids="53310">copolymer</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>GE11 <z:chebi fb="5" ids="53310">copolymer</z:chebi> conjugate binds specifically and efficiently to EGFR over-expressing cells, thus mediating internalisation to a significantly higher extent relative the <z:chebi fb="5" ids="53310">copolymer</z:chebi> conjugated to a scrambled sequence <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>We further incorporated <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (DOX) into GE11 bearing <z:chebi fb="5" ids="53310">copolymer</z:chebi> via an acid-labile <z:chebi fb="0" ids="38532">hydrazone</z:chebi> bond </plain></SENT>
<SENT sid="6" pm="."><plain>The GE11-DOX <z:chebi fb="5" ids="53310">copolymer</z:chebi> conjugate demonstrated higher cytotoxicity toward EGFR over-expressing cells relative to the control non-targeted DOX conjugate </plain></SENT>
<SENT sid="7" pm="."><plain>Altogether, our results show a proof of principle for the selective delivery of DOX to the target <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
</text></document>